The two oral antiviral therapeutics developed by pharmaceutical companies Merck and Pfizer to treat mild to moderate cases of COVID-19 are readily available to patients in Tennessee as a part of an increased bi-weekly allocation program.
“This increase in allocations is something we have been anticipating for weeks,” Tennessee Department of Health Commissioner Dr. Lisa Piercey, MD, MBA, FAAP said in a statement. “Our goal has always been to increase access to these treatments by onboarding more pharmacies to maximize access to patients. We have seen a steady increase in allocations to the state and know many pharmacies and providers are eager to offer this treatment to help mitigate COVID-19 disease progression for those at risk of a severe outcome.”
Read More